Cargando…
Taux des plaquettes sanguines en phase intercritique et expressivité clinique de la drépanocytose dans un centre de référence de la drépanocytose au Mali
Risk factors associated with complications occurring in sickle cell disease are not fully elucidated. The purpose of this study was to evaluate the existence of an association between the clinical severity of sickle cell disease and platelet count in the steady state phase in patients with sickle ce...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The African Field Epidemiology Network
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755550/ https://www.ncbi.nlm.nih.gov/pubmed/36578815 http://dx.doi.org/10.11604/pamj.2022.43.52.32674 |
_version_ | 1784851445912174592 |
---|---|
author | Diallo, Lamine Guindo, Aldiouma Kéita, Ibrahima Baraïka, Mohamed Ag Dembélé, Abdoul Karim Touré, Boubacari Ali Diallo, Dapa Aly |
author_facet | Diallo, Lamine Guindo, Aldiouma Kéita, Ibrahima Baraïka, Mohamed Ag Dembélé, Abdoul Karim Touré, Boubacari Ali Diallo, Dapa Aly |
author_sort | Diallo, Lamine |
collection | PubMed |
description | Risk factors associated with complications occurring in sickle cell disease are not fully elucidated. The purpose of this study was to evaluate the existence of an association between the clinical severity of sickle cell disease and platelet count in the steady state phase in patients with sickle cell disease followed up at the Center for Research and Control of Sickle Cell Disease in Bamako, Mali. We conducted a retrospective review of 40 medical records of patients aged 5 to 42 years with sickle cell disease at the Center for Research and Control of Sickle Cell Disease in Bamako, Mali. Clinical severity of sickle cell disease was assessed according to the criteria of VOC and/or hospitalizations < 2 or ≥ 2 per year. Data entry was carried out using the Excel 2013 version. The statistical tests used were the Chi2, Student and Mac Nemar tests. Of the 40 patients, 82.5% had haemolytic phenotype and 17.5% hyperviscous phenotype; complications of sickle cell disease were more frequent in the haemolytic phenotype group (p < 0.05). There was a significant association between mean platelet count ≥ 450 G/L in the steady state phase and the annual number of CVOs ≥ 2 (p = 0.002). This study shows that mean platelet count ≥ 450 G/L in sickle cell patients in the steady state phase could be a risk factor for the frequent occurrence of CVO. It underlines the importance of conducting prospective studies focusing on both hyperplateletosis and platelet activation markers in larger sample sizes, as well as therapeutic trials involving platelet activation inhibitors, such as Crizanlizumab, a humanised anti-P-selectin monoclonal antibodies. |
format | Online Article Text |
id | pubmed-9755550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The African Field Epidemiology Network |
record_format | MEDLINE/PubMed |
spelling | pubmed-97555502022-12-27 Taux des plaquettes sanguines en phase intercritique et expressivité clinique de la drépanocytose dans un centre de référence de la drépanocytose au Mali Diallo, Lamine Guindo, Aldiouma Kéita, Ibrahima Baraïka, Mohamed Ag Dembélé, Abdoul Karim Touré, Boubacari Ali Diallo, Dapa Aly Pan Afr Med J Short Communication Risk factors associated with complications occurring in sickle cell disease are not fully elucidated. The purpose of this study was to evaluate the existence of an association between the clinical severity of sickle cell disease and platelet count in the steady state phase in patients with sickle cell disease followed up at the Center for Research and Control of Sickle Cell Disease in Bamako, Mali. We conducted a retrospective review of 40 medical records of patients aged 5 to 42 years with sickle cell disease at the Center for Research and Control of Sickle Cell Disease in Bamako, Mali. Clinical severity of sickle cell disease was assessed according to the criteria of VOC and/or hospitalizations < 2 or ≥ 2 per year. Data entry was carried out using the Excel 2013 version. The statistical tests used were the Chi2, Student and Mac Nemar tests. Of the 40 patients, 82.5% had haemolytic phenotype and 17.5% hyperviscous phenotype; complications of sickle cell disease were more frequent in the haemolytic phenotype group (p < 0.05). There was a significant association between mean platelet count ≥ 450 G/L in the steady state phase and the annual number of CVOs ≥ 2 (p = 0.002). This study shows that mean platelet count ≥ 450 G/L in sickle cell patients in the steady state phase could be a risk factor for the frequent occurrence of CVO. It underlines the importance of conducting prospective studies focusing on both hyperplateletosis and platelet activation markers in larger sample sizes, as well as therapeutic trials involving platelet activation inhibitors, such as Crizanlizumab, a humanised anti-P-selectin monoclonal antibodies. The African Field Epidemiology Network 2022-10-03 /pmc/articles/PMC9755550/ /pubmed/36578815 http://dx.doi.org/10.11604/pamj.2022.43.52.32674 Text en Copyright: Lamine Aly Diallo et al. https://creativecommons.org/licenses/by/4.0/The Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Diallo, Lamine Guindo, Aldiouma Kéita, Ibrahima Baraïka, Mohamed Ag Dembélé, Abdoul Karim Touré, Boubacari Ali Diallo, Dapa Aly Taux des plaquettes sanguines en phase intercritique et expressivité clinique de la drépanocytose dans un centre de référence de la drépanocytose au Mali |
title | Taux des plaquettes sanguines en phase intercritique et expressivité clinique de la drépanocytose dans un centre de référence de la drépanocytose au Mali |
title_full | Taux des plaquettes sanguines en phase intercritique et expressivité clinique de la drépanocytose dans un centre de référence de la drépanocytose au Mali |
title_fullStr | Taux des plaquettes sanguines en phase intercritique et expressivité clinique de la drépanocytose dans un centre de référence de la drépanocytose au Mali |
title_full_unstemmed | Taux des plaquettes sanguines en phase intercritique et expressivité clinique de la drépanocytose dans un centre de référence de la drépanocytose au Mali |
title_short | Taux des plaquettes sanguines en phase intercritique et expressivité clinique de la drépanocytose dans un centre de référence de la drépanocytose au Mali |
title_sort | taux des plaquettes sanguines en phase intercritique et expressivité clinique de la drépanocytose dans un centre de référence de la drépanocytose au mali |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755550/ https://www.ncbi.nlm.nih.gov/pubmed/36578815 http://dx.doi.org/10.11604/pamj.2022.43.52.32674 |
work_keys_str_mv | AT diallolamine tauxdesplaquettessanguinesenphaseintercritiqueetexpressivitecliniquedeladrepanocytosedansuncentredereferencedeladrepanocytoseaumali AT guindoaldiouma tauxdesplaquettessanguinesenphaseintercritiqueetexpressivitecliniquedeladrepanocytosedansuncentredereferencedeladrepanocytoseaumali AT keitaibrahima tauxdesplaquettessanguinesenphaseintercritiqueetexpressivitecliniquedeladrepanocytosedansuncentredereferencedeladrepanocytoseaumali AT baraikamohamedag tauxdesplaquettessanguinesenphaseintercritiqueetexpressivitecliniquedeladrepanocytosedansuncentredereferencedeladrepanocytoseaumali AT dembeleabdoulkarim tauxdesplaquettessanguinesenphaseintercritiqueetexpressivitecliniquedeladrepanocytosedansuncentredereferencedeladrepanocytoseaumali AT toureboubacariali tauxdesplaquettessanguinesenphaseintercritiqueetexpressivitecliniquedeladrepanocytosedansuncentredereferencedeladrepanocytoseaumali AT diallodapaaly tauxdesplaquettessanguinesenphaseintercritiqueetexpressivitecliniquedeladrepanocytosedansuncentredereferencedeladrepanocytoseaumali |